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Abstract Arrhythmogenic cardiomyopathy (ACM) is a ge-
netic cardiac condition characterized by the replacement of
the ventricular myocardiumwith fibro-fatty tissue, by arrhyth-
mias and sudden death. Adipogenesis in ACM is considered
an aberrant remodeling following myocardial loss. Which cell
type(s) is (are) responsible for the adipose replacement is still
matter of debate. A systematic overview of the different cells
that have been, over time, considered as main players in adi-
pose replacement is provided. The comprehension of the cel-
lular component giving rise to arrhythmogenic cardiomyopa-
thy substrate defects may represent both an essential tool for
mechanistic studies of disease pathogenesis and a novel pos-
sible therapeutic target.
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Introduction
Arrhythmogenic cardiomyopathy (ACM) is a genetic severe
cardiac condition predominantly affecting the right ventricle
with unfavorable prognosis due to malignant ventricular ar-
rhythmias and heart failure (HF). The pathological hallmark of
the disease is a progressive loss of contractile myocardium,
that is replaced by fibrous and adipose tissue [1]. This fibro-
fatty substitution process extends transmurally with an epi-
endocardial gradient, causing ventricular free wall thinning
and aneurysmal dilation, especially in the so-called triangle
of dysplasia (inflow tract, outflow tract, and apex) [2] of the
right ventricle. Fibro-fatty substitution constitutes a part of the
substrate that determines the worsening of the arrhythmogenic
phenotype [3, 4]. ACM is characterized by typical electrocar-
diographic features (ε waves, right precordial QRS
prolongation, T-wave inversion) and life-threatening ventric-
ular arrhythmias, usually with a left bundle branch block [5].
Moreover, fibro-fatty substitution provokes progressive re-
gional and global biventricular dysfunction [6] and ultimately
congestive heart failure.
PKP2 and the other desmosomal genes are frequently mu-
tated in ACM [7], causing alterations of intermediate filament-
mediated anchorage of cardiac cells to each other, impairing
tissue structural integrity, electrical conduction, mechanical
contraction, and cellular functionality [8]. To date, enough
evidence has been provided indicating that electrical instabil-
ity in ACM is caused by cardiomyocyte defects, including
dysregulation of sodium channels, gap junctions, and intracel-
lular calcium handling processes, and ultimately by cardio-
myocyte death [4]. On the contrary, adipose replacement,
which is likely to be attributed to a defective remodeling fol-
lowing myocardial loss [9], lacks an indisputable proof about
its origin.
Cardiomyocyte loss has been attributed to different patho-
genic mechanisms, among which stretch-induced cell damage
[10] facilitated by desmosomal mutations. Moreover, since
inflammatory infiltrates have been found in ACM hearts, the
co-occurrence of myocarditis has been postulated to further
produce cardiomyocyte injury and death [11]. Finally, the
myocyte apoptotic theory has been formulated due to the high
levels of CPP-32, a cysteine protease required for apoptosis,
detected in ACM patients’ hearts [12]. Whatever the reason,
cardiomyocytes die and subsequently fibro-fatty substitution
occurs.
The Binfiltrative theory^ of cells from the epicardial layer
[13] has been advanced as a plausible hypothesis for fibro-
fatty substitution, according to evidence at both tissue and
clinical levels that fibro-fatty infiltration progresses from the
epicardium towards the endocardium [14].
On the contrary, the Bdifferentiation theory^ proposes that
resident cardiac cells differentiate into adipocytes, through
Wnt pathway alterations. Indeed, it was hypothesized that an
altered desmosomal structure could provoke plakoglobin (PG)
translocation to the nucleus, where it could induce cell tran-
scriptional activity changes. This could lead to the increase of
adipogenic and fibrogenic gene expression, thus contributing
to differentiation [15]. However, PG nuclear translocation,
demonstrated in vitro by different groups [15–18], has been
questioned in human pathological ACM heart tissues [19].
Recently, the Hippo pathway, activated by mechanical
stress, G-protein-coupled receptor signaling, and oxidative
stress [20], has been found involved, with the effect of
dysregulating cell proliferation/apoptosis and further sup-
pressing Wnt pathway [21].
Although both theories are supported by a strong rationale,
so far a single theory has not been exclusively proven by clear-
cut evidence. Which cell type(s) is (are) responsible for the
aberrant adipogenic differentiation process is therefore still an
open and burning question. This review aims to provide a
systematic overview about possible cell effectors that have
been proposed as players of adipose replacement in ACM
and is meant to provide a new vision of the mechanisms of
fibro-fatty development, in an attempt to harmonize the Bin-
filtrative^ and Bdifferentiation^ theories.
Mechanisms of Adipogenesis
The comprehension of molecular mechanisms underpinning
adipose tissue development is crucial to characterize the pres-
ence of adipocytes in ACM hearts. This phenomenon in ACM
occurs through a proper adipogenic differentiation process
producing mature adipocytes (adipogenesis), and not mere
cellular lipid accumulation (lipogenesis).
In adipose tissue, adipocyte formation is a multifaceted and
stepwise differentiation process involving many mediators
(Fig. 1). Adipocytes derive from adipose tissue-
mesenchymal stromal cells (A-MSC), differentiating at first
into lipoblasts, then to preadipocytes and finally into mature
adipocytes [22]. The acquisition of the adipocyte phenotype is
characterized by sequential changes in the expression of many
genes [23]. The primary factors activated by adipogenic stim-
uli are CCAAT/enhancer-binding proteins (C/EBPs) β and δ,
that are responsible for peroxisome proliferator-activated re-
ceptor gamma (PPARγ) and C/EBP-α expression increase, in
parallel with cell growth arrest [24]. PPARγ and C/EBPα
mutually reinforce positive regulatory loops ensuring their
high-level expression. Moreover, sterol regulatory element
binding protein 1 (SREBP1) transcription factor is induced
at the early stages of the adipogenic process [25].
PPARγ is the master regulator, being essential for the
adipogenic process [26]. Its expression progressively increases
to allow the adipogenic switch [23]. It is regulated by several
known signals, among which Wnt pathway is one of the major
negative mediators [27]. The canonical Wnt pathway is
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activated by Wnt ligands leading to the translocation of β-
catenin into the nucleus, where it binds the T cell/lymphoid
enhancer factor (TCF/LEF) transcription factors, stimulating
proliferation genes [28]. When Wnt is inhibited, a switch oc-
curs between proliferation and adipogenic fate.
The inhibition of sonic hedgehog (SHH) pathway triggers
adipocyte differentiation, even if alone is not sufficient to suc-
ceed in [29]. SHH may induce anti-adipogenic effects by en-
hancing GATA binding protein 2 (GATA2) expression, lead-
ing to the inhibition of PPARγ and C/EBPα expression [30].
Bone morphogenetic proteins (BMPs), proteins of the
transforming growth factor β (TGFβ) super-family, can in-
duce adipogenesis through the activation of Smad transcrip-
tion factors and p38 mitogen-activated protein kinase
(MAPK) pathway [31].
AMP-activated protein kinase (AMPK) is involved in the
negative regulation of adipogenesis. It blocks the expression
of PPARγ and C/EBPα and promotes apoptosis [32].
When complexed with its ligands, the insulin-like
growth factor receptor (IGFR)-1 can activate different
downstream effectors, among which phosphatidyl inositol
3-kinase (PI3K), leading to the activation of the serine
threonine kinase Akt cascade, thus stimulating adipogen-
esis [33]. A link is known between PI3K and Notch sig-
naling. In particular, phosphatase and tensin homolog
(PTEN) was demonstrated to be a negative regulator of
the PI3K pathway [34].
The induction of adipogenesis is promoted by glucocorti-
coids, through the activation of C/EBPβ [35], cAMP respon-
sive element binding protein (CREB) through the increase of
Fig. 1 Common mechanisms of adipogenic differentiation in adipose
tissue and in arrhythmogenic cardiomyopathy (ACM) hearts. The
differentiation of adipose tissue-mesenchymal stromal cells (A-MSC)
to adipocytes is driven by different signaling pathways, transcription
factors, and epigenetic mechanisms. The box on the left highlights the
complex regulation of adipogenesis, including the mechanisms
responsible of inhibition (in red) and stimulation (in green) of adipocyte
formation. In the right part of the figure, transcript upregulation during A-
MSC differentiation into preadipocytes and then adipocytes is illustrated.
The orange writing represents the cell source (cardiac mesenchymal
stromal cells (C-MSC)), and the mechanisms of adipogenesis
demonstrated in ACM. AKT protein kinase B, AMPK AMP-activated
protein kinase, BMPs bone morphogenetic proteins, CEBPs
CCAAT/enhancer-binding proteins, CREB cAMP responsive element
binding protein, FABP4 fatty acid-binding protein 4, GATA2 GATA
binding protein 2, GLUT4 glucose transporter type 4, IFN-γ interferon-
γ, IGFR-1 insulin-like growth factor receptor, IL-6 interleukin, LIPE
lipase, p38 protein 38, PI3K phosphatidyl inositol 3-kinase, PLIN
perilipin, PPARγ peroxisome proliferator-activated receptor-γ, pRB
retinoblastoma proteins, PTEN phosphatase and tensin homolog, ROS
reactive oxygen species, SHH sonic hedgehog, SREBP1 sterol regulatory
element binding protein 1, TNF-α tumor necrosis factor-alpha
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PPARγ expression [36], and retinoblastoma (pRb) family pro-
teins through direct interaction with C/EBPs [37].
Other factors able to modulate adipogenesis are reactive
oxygen species (ROS) and free radicals, that can interact with
preadipocytes to prompt their differentiation [38].
On the contrary, pro-inflammatory cytokines such as tumor
necrosis factor-alpha (TNF-α), interleukin (IL)-6, and
interferon-γ (IFN-γ) inhibit preadipocyte differentiation and
lipid accumulation [39–41].
In addition to transcription changes induced by transcrip-
tion factors, also epigenetic mechanisms andmicroRNAs, fine
regulators of gene expression, are involved in the adipogenic
process [42].
At later phases, when preadipocytes have committed to the
adipogenesis program, activation of metabolic genes and
adipokines occurs, such as fatty acid-binding protein 4
(FABP4), glucose transporter 4 (GLUT4), leptin, and
adiponectin [27]. Increased levels of total adrenergic receptors
are also reported [23]. In addition, adipocytes synthesize other
adipose tissue-specific products, such as perilipins, lipid
droplet-surrounding proteins [43], hormone-sensitive lipase,
that hydrolyzes stored triglycerides to free fatty acids [44],
and the fatty acid transporter CD36 [23]. This process pro-
vokes changes in cell morphology, with conversion from fi-
broblastic to spherical shape, along with modifications of cy-
toskeletal and extracellular matrix components [23].
Analogies can be found in the differentiation process oc-
curring in adipose tissue and in ACM hearts. As described, the
involvement of certain adipogenic pathways is clearly
established in ACM [3, 15, 16, 45] (Fig. 1). Indeed, as men-
tioned above, Wnt/β-catenin pathway and different
microRNAs have been shown to ultimately affect the
C/EBPα-PPARγ axis in ACM. Mutated cells upregulate
adipogenic transcripts, such as FABP4 and adiponectin, and
proceed to differentiation into mature PLIN-expressing adipo-
cytes (Fig. 1). Other adipogenic mechanisms are still unex-
plored, even if potentially involved.
Which Cell Is the Source of Fibro-Fatty Substitution
in ACM?
Cardiomyocyte Transdifferentiation
The hypothesis that adipocytes in ACM hearts derive from
cardiomyocyte transdifferentiation has gained in the past a
widespread consensus. Interestingly, a single report, published
more than 15 years ago, described that the histological, immu-
nochemical, and ultrastructural analysis of an ACM heart was
suggestive of cardiomyocyte adipogenic transdifferentiation
[46]. The authors found, in both ventricles, that
cardiomyocytes contiguous to the adipose tissue showed, in-
stead of the myofibril component, multiple sarcoplasmic
vacuoles, that made these cells indistinguishable from
preadipocytes. By means of immunohistochemistry staining
for desmin to mark muscle tissue, and vimentin, a protein
expressed in adipocytes and absent in adult cardiomyocytes
[46], they observed that a few myocytes showing cytoplasmic
vacuoles were positive for both these markers. They
interpreted these cells as transitional elements between
cardiomyocytes and fat cells. However, vimentin is not exclu-
sively expressed in adipocytes, being a major cytoskeletal
component of mesenchymal cells; therefore, this evidence is
not per se demonstrative of myocyte transdifferentiation. This
evidence has never been confirmed to date. In a recent work,
we could not detect in human ACM hearts cardiomyocyte
positivity for the adipocyte specific marker PLIN1 as well as
preadipocyte positivity for α-sarcomeric actin [16]. Thus,
this evidence excludes a direct contribution of adult cardio-
myocyte transdifferentiation into adipocytes.
Interestingly, in 2008, Fujita et al. [47] observed in an
ACM patient’s heart biopsy a large amount of adipose tissue
and a group of isolated myocardial cells with an island-like
appearance between the adipocytes. Analyzing this group of
cardiomyocytes, they detected polymorphic nuclear changes in
shape, perinuclear vacuolization, and accumulation of small
granules, which visually appeared similar to lipid droplets. By
means of electron microscopy, they speculated on the pres-
ence of lipid droplets of various sizes in the cardiomyocytes.
This phenomenon was accompanied by degeneration of intra-
cellular organelles and occasional disruption of the plasma
membrane with discharge of intracellular content, including
mitochondria, into the interstitial space [47], all being charac-
teristics of cellular autophagy [48]. Although the microscopic
analysis is not conclusive for cardiomyocyte lipid accumula-
tion, a limited lipogenesis (fat droplet accumulation) may oc-
cur in myocytes [45]. It is then conceivable that the contractile
heart compartment undergoes lipogenesis rather than adipo-
genesis in ACM. Of note, intracellular fat droplet accumula-
tion has the potential to impact on myocardial function [49].
Cardiac Progenitor Cells
As an alternative causative mechanism, cardiac progenitor
cells expressing desmosomal proteins have been postulated
to be responsible for adipocyte differentiation in ACM hearts.
Taking advantage of genetic fate-mapping experiments in
mice, second heart field-derived progenitor cells, character-
ized by Isl-1, an early marker of multipotent mesodermal pre-
cursors, have been shown to take part to adipogenesis. This
finding was corroborated in ACM human hearts by the evi-
dence of co-expression of second heart field markers and
adipogenic transcription factors [50]. Notably, Isl-1 cell ex-
pansion has been related to Wnt signaling [51]. On this basis,
it has been suggested that the adipogenic switch of these pre-
cursors may occur before myocyte commitment, depending
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on the suppression of canonical Wnt pathway signaling by
nuclear PG translocation [50]. However, the small number
of Isl-1+ preadipocytes found in ACM hearts [50] is a strong
limitation challenging this hypothesis. Moreover, the
embryologic origin of cardiac progenitors from the second
heart field cannot provide an exhaustive explanation for the
left-predominant or biventricular forms of ACM [52].
A further hypothesis involving cardiac precursors is
based on the common developmental origin of second
heart field RV progenitors and epicardial cells [53].
Epicardial cells, giving rise to non-myocyte stromal com-
ponents through epithelial-to-mesenchymal transition
(EMT) [54], have been proposed as source of adipocytes
in ACM [13]. Indeed, Matthes et al. demonstrated that
epicardium-derived cells obtained from neonatal hearts
express desmosomes, and, if silenced for PKP2, they have
increased migration velocity, higher proliferative rate, and
can be driven to adipogenesis. These cells have been in
fact suggested to cause excess of fibroblasts, adipocytes,
or their progenitors, in the myocardial interstitium [13].
As an E-cadherin negative and α-smooth muscle actin (α-
sma) positive subpopulation was identified, the authors
hypothesized that this epicardial cell subpopulation may
correspond to resident myofibroblast, or alternatively cells
in which EMT occurred [13]. After PKP2 silencing, an
increase in α-sma-positive cells was reported, and it was
not clear whether it depended on cell proliferation or on a
boost of EMT. Indeed, in EMT process, both E-cadherin
and PKP2 are known to be downregulated [55], raising
the intriguing hypothesis that PKP2 loss could be associ-
ated to EMT. The epicardium-endocardium gradient of the
ACM adipose substitution is a key element supporting
this theory [9].
Alternatively, c-kit+/Sca1+ progenitor cells have also
been proposed as adipocyte precursors [17]. Lombardi
et al. in 2011 generated transgenic mice overexpressing
wild-type and truncated PG. Histological examination
showed a moderate increased number of adipocytes, pre-
dominantly in the epicardium, and fibrosis in the heart of
these transgenic models. Moreover, they exhibited cardiac
dysfunction and premature death. The authors isolated c-
kit+/Sca1+ cells from PG transgenic mice, and they ob-
tained adipogenic differentiation of these cells through
the contribution of Wnt signaling [17]. Since c-kit+/
Sca1+ cells from PG homozygous knockout embryos have
been shown to be resistant to adipogenesis and showed
normal activation of canonical Wnt pathway, they demon-
strated the role of PG in the induction of lipid accumula-
tion in these cells [17]. However, a quantitative evaluation
providing evidence on the effective contribution of these
cardiac progenitor cells on adipogenesis is currently lack-
ing [56]. Our recent findings revealed that the percentage
of c-kit+ preadipocytes in the human ACM myocardium is
too low to account for the massive adipocyte presence in
ACM hearts, suggesting that only a small proportion of
adipocytes in ACM may ultimately originate from c-kit+
progenitors [16].
Differentiation of Pluripotent Cells
In 2016, we introduced for the first time a novel hypothesis on
the origin of ectopic adipocytes in ACM [16], identifying
cardiac mesenchymal stromal cells (C-MSC) as an adult,
non-contractile cell compartment involved in lipid accumula-
tion and adipogenic differentiation [16]. C-MSC are a large
population of supportive cells of epicardial origin, character-
ized by multipotency. They play a critical role in maintaining
healthy heart structure and function. Importantly, C-MSC are
involved in cardiac remodeling in pathological conditions
[57]. Noteworthy, as for A-MSC, C-MSC can differentiate
into adipocytes under appropriate stimuli.
First of all, to understand the cellular origin of adipocytes in
ACM hearts, we performed immunofluorescence staining on
ACM cardiac tissue, finding cells actively differentiating into
adipocytes expressing the typical mesenchymal markers
CD29 and CD105 [16].
Moreover, we isolated C-MSC from ACM and control
heart biopsy specimens, and we demonstrated that C-MSC
express desmosomal genes, and therefore suffer the conse-
quence of desmosomal mutations. Importantly, C-MSC from
ACM patients’ hearts have been shown to differentiate into
adipocytes in culture, by both phenotypic analysis and expres-
sion analysis of specific adipogenic genes and relative pro-
teins. We also tested the involvement of the Wnt pathway,
increasing its activity by inhibiting glycogen synthase kinase
3 beta (GSK3β), and obtained a reduction in the accumulation
of lipid droplets. Since PKP2 is expressed at lower levels in
ACM C-MSC, not only when obtained from PKP2 mutation
carriers but also when obtained from patients without a known
mutation, we evaluated if adipogenic differentiation occurs
through a common PKP2-dependent mechanism. Indeed,
the overexpression of PKP2 led to a decrease of lipid accu-
mulation in ACM cells. In contrast, silencing PKP2 in control
cells, we obtained a significant increase of adipogenesis. All
together, these findings provide convincing evidence that C-
MSC are a source of adipocytes in ACM. In the future,
genotype/phenotype studies need to be performed in order to
understand any differential propensity of C-MSC lipid accu-
mulation in different desmosomal or non-desmosomal muta-
tion carriers.
More recently, cardiac fibro-adipose progenitors (FAP)
characterized by the expression of PDGFRα have been pro-
posed as source of both adipocytes and fibrosis [58], as pre-
viously suggested by Paylor and colleagues [56] and as dem-
onstrated by the expression of either adipogenic or fibrogenic
markers. FAP progenitors contribute to the vascular and
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mesenchymal compartments of the human hearts and descend
from epicardial derivatives, being PDGFRα necessary for
EMT[59]. Lombardi et al. demonstrated that the subset of
FAP that expresses the adipogenic marker C/EBP-α expresses
also desmosomal genes, and, if mutated, can differentiate into
adipocytes through the suppression of canonical Wnt signal-
ing in ACM caused by DSP haploinsufficiency. Cardiac FAP
gives origin to approximately 40% of adipocytes in the heart
of an ACM mouse model, indicating the possibility of the co-
existence of another cellular origin of lipid accumulation in
ACM. Further experiments will be needed to ascertain com-
munalities and differences of C-MSC [16] with FAP subpop-
ulation [58] in ACM pathogenesis.
Inferences and Conclusions
Research in ACM has recently progressed from clinical,
genetic, and mechanistic standpoints. Pathogenic information
is however still missing for a complete understanding of ACM
etiology, even if scientific consensus exists on key points as
follows:
1. It is now widely accepted that cardiomyocyte death con-
stitutes the primummovens in disease pathogenesis, either
apoptotic [12] or secondary to mechanical stretch [10] or
infections [11].
2. Aberrant remodeling after cardiomyocyte death takes
place through signaling pathways [15, 21] specifically
driven by desmosomal gene mutations, resulting in
overdepos i t i on o f ex t r ace l lu l a r ma t r ix and
desmosome-expressing cell differentiation into
adipocytes.
Relevant steps forward have been undertaken over time in
the understanding of fibro-fatty pathogenesis and cellular ef-
fectors (Table 1). As outlined in this manuscript, cardiomyo-
cyte transdifferentiation is unlikely to happen. Furthermore,
cardiac progenitors are present in a too low rate in an adult
heart to account to a wide effect contribution. Most likely,
epicardial cells, highly expressing desmosomal genes, as all
epithelia, undergo EMT, of which Wnt represents a contribut-
ing pathway, resulting in a centripetal invasion of mesenchy-
mal cells from the epicardium to the endocardium, both in
ACM and in physiological conditions. C-MSC are character-
ized by a lower expression of desmosomal genes with respect
to epithelial cells; particularly, the further reduction of desmo-
somal proteins in ACM C-MSC may be the culprit for the
adipogenic switch. Indeed, C-MSC or a C-MSC subpopula-
tion are well known to possess a differentiation ability into
adipocytes.
Table 1 Summary of all cells proposed as candidate sources of adipocytes in ACM hearts
Cell Reference Species Strengths Weakness
Cardiomyocyte D’Amati et al. [46] Human - Cardiomyocytes highly express
desmosomal proteins.
- No demonstration of cardiomyocyte
adipogenic differentiation.
Fujita et al. [47] - Not demonstrative of cardiomyocyte
adipogenic differentiation.
- Lipogenesis only.
Cardiac
progenitor
Lombardi et al. [50] Mouse - Co-expression of second heart field markers
and adipogenic transcription factors.
- Is1-1+ cell expansion is related to Wnt signaling.
- Small number of Is1-1+ cells in an
adult heart.
- Do not explain biventricular and left
forms of ACM.
- Demonstrated in animal model only.
Matthes et al. [13] Rat - Epicardial cells express desmosomal proteins.
- If silenced for PKP2, increased their migration
velocity, proliferative rate, and accumulate lipids.
- Small number of epicardial cells in an
adult heart.
- Demonstrated in animal model only.
Lombardi et al. [17] Mouse - c-kit+/Scal+ cells undergo adipogenic
differentiation, with the involvement of PG.
- Small number of c-kit+/Scal+ cells in an
adult heart.
- Demonstrated in animal model only.
Pluripotent cell Sommariva et al. [16] Human - C-MSC express desmosomal proteins.
- Preadipocytes in ACM hearts are of mesenchymal
origin.
- C-MSC undergo adipogenic differentiation
with the involvement of Wnt.
- Need for further characterization.
Lombardi et al. [58] Human/mouse - FAP express desmosomal proteins.
- FAP undergo adipogenic differentiation
with the involvement of Wnt.
- FAP are not the only responsible for
ACM cardiac adipocytes.
- No evidence on patients’ hearts.
The strengths and weakness of the different studies are listed.
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Whether adipogenesis in ACM hearts represents distorted
wound healing or has a distinct functional role in disease path-
ogenesis is still not known. Electrically inert tissue may in-
duce compulsory current routes through the remaining
cardiomyocytes, exacerbating ACM arrhythmic phenotype.
Moreover, adipose tissue is known to exert a strong paracrine
activity, influencing both inflammation and cardiomyocyte
contractility performances by attenuating intracellular calcium
ion levels [60].
Overall, a comprehensive understanding of the fibro-fatty
substitution process in ACM is today a matter of active scien-
tific debate with potential relevant repercussion at clinical lev-
el, since the cellular component giving rise to substrate defects
may represent both an essential tool for mechanistic studies of
ACM pathogenesis and a possible novel therapeutic target.
Indeed, the in vitro study of the adipogenesis process in the
cells responsible for the adipose tissue deposition in ACM
may give scientists the tools to counteract it by directly in-
volved pathways. Another interesting option may be to assess
a potential therapeutic effect by means of high-throughput
screenings of FDA-approved drugs or new druggable com-
pounds. Perspectively, targeted cell-specific administration
could be envisaged, in order to avoid systemic effects.
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